



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Zolbetuximab

Cat. No.:	HY-P99058
CAS No.:	1496553-00-4
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors ^[1] .	
In Vitro	Zolbetuximab (0-100 µg/mL) binds to CLDN18.2 ⁺ PC cells, and induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Zolbetuximab (200 µg, i.v.) alone and in combination with Gemcitabine (HY-17026) (50 mg/kg, i.p.) exhibits antitumor activity in mouse BxPC-3-CLDN18.2 xenograft models ^[2] . Zolbetuximab (5.7 mg/kg, i.p., three times per week for five weeks) inhibits tumor growth in SNU-620 cells xenograft model ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model ^[2]
	Dosage:	200 µg alone or with 50 mg/kg Gemcitabine
	Administration:	i.v.; i.p. (Gemcitabine)
	Result:	Inhibited tumor growth in two models, and prevented lung metastasis formation. Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft.

REFERENCES

- [1]. Türeci Ö, et al. Characterization of zolbetuximab in pancreatic cancer models. *Oncoimmunology*. 2018 Nov 10;8(1):e1523096.
- [2]. Zhong W, et al. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers. *Front Immunol*. 2022 Jun 28;13:885424.
- [3]. Kyuno D, et, al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. *Tissue Barriers*. 2022 Jan 2;10(1):1967080.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA